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Abstract 
Background: Statins are well established LDL-cholesterol-lowering drugs. Elevated Apo CIII 
levels are associated with elevated triglyceride-rich particles which are also considered to be a 
possible risk factor for CVD.  
Objective: The aim of this meta-analysis of randomized placebo-controlled clinical trials was to 
assess the effect of statins on Apo CIII concentrations.  
Methods: Randomized placebo-controlled trials investigating the impact of statin treatment on 
cholesterol lowering that include lipoprotein measurement were searched in PubMed-Medline, 
SCOPUS, Web of Science and Google Scholar databases (up to July 31, 2017). A random-effects 
model and generic inverse variance method were used for quantitative data synthesis. Sensitivity 
analysis was conducted using the leave-one-out method. A weighted random-effects meta-
regression was performed to evaluate the impact of potential confounders on Apo CIII 
concentrations. 
Results: This meta-analysis of data from 6 randomized placebo-controlled clinical trials (10 
statin arms) involving 802 subjects showed that statin therapy significantly decreased circulating 
Apo CIII concentrations (weighted mean difference [WMD]: -2.71, 95% CI: -3.74, -1.68, 
p<0.001; I2: 73.83%). The effect size was robust in the leave-one-out sensitivity analysis and not 
driven by any single study. Subgroup analysis showed a reduction of Apo CIII concentrations by 
atorvastatin (WMD: -4.74, 95% CI: -3.74, -1.68, p=0.002; I2: 84.02%), rosuvastatin (WMD: -
2.68, 95% CI: -4.52, -0.84, p=0.004; I2: 0%) and lovastatin (WMD: -1.64, 95% CI: -2.22, -1.07, 
p<0.001; I2: 0%).  
Conclusion: This meta-analysis suggests that statin treatment significantly reduces plasma Apo 
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CIII levels.  
Keywords: apolipoprotein CIII; statins; cardiovascular disease; atorvastatin; rosuvastatin; 
lovastatin 
 
Introduction 
Statins are well established low density lipoprotein cholesterol (LDL-C)-lowering drugs with 
proven efficacy in reducing cardiovascular disease (CVD) morbidity and mortality, both in 
primary and secondary prevention.1-3 Statins also reduce triglycerides (TG) levels and 
moderately raise high density lipoprotein cholesterol (HDL-C) levels.4 This statin effect depends 
on the pre-treatment TG level and the LDL-C lowering effect of the statin. 
In addition to plasma lipids and lipoproteins, statins also exert several pleiotropic effects relevant 
to the reduction of CVD risk.5-7 Apolipoprotein (Apo) CIII, described almost half a century ago, 
is crucial in regulating TG metabolism because it inhibits lipoprotein lipase and hepatic lipase 
activity as well as hepatic uptake of TG-rich lipoproteins.4,8,9,10  
 
Elevated Apo CIII levels are therefore associated with elevated TG levels which are considered 
to be a possible risk factor for CVD.4,11 Elevated plasma TG and low HDL-C levels are not only 
predictors for macrovascular atherosclerotic disease and CVD events but they are also risk 
factors for microvascular disease in type 2 diabetes mellitus (T2DM).12 Because of these effects, 
elevated Apo CIII levels are considered as markers/predictors of CVD risk.13-15 This concept has 
been supported relatively recently by finding that loss-of-function in APOC3 mutations are 
associated with low TG concentrations and reduced CVD risk.16-18 
There are still some open questions concerning the effect of statin treatment on Apo CIII levels. 
Furthermore, the results of some trials that evaluated this relationship are contradictory. 
Therefore, we performed a meta-analysis of randomized controlled trials that assessed this 
relationship. 
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Methods  
Search Strategy 
This study was designed according to the guidelines of the preferred reporting items for 
systematic reviews and meta-analysis (PRISMA) statement.19 PubMed-Medline, Scopus and ISI 
Web of Knowledge databases were searched using the following search terms in titles and 
abstracts: Atorvastatin OR mevastatin OR lovastatin OR simvastatin OR fluvastatin OR 
rosuvastatin OR pitavastatin OR pravastatin) AND (Apo CIII OR Apo C-III OR "apo CIII" OR 
"apo C-III" OR apoC3 OR "apo C3") AND placebo. The wild-card term ‘‘*’’ was used to 
increase the sensitivity of the search strategy by considering all interchangeable formats of 
search terms. The search was limited to articles published in English. The literature was searched 
from inception to July 31, 2017. 
 Study Selection 
Original studies were included if they met the following criteria: (i) randomized placebo-
controlled clinical trial with either parallel or cross-over design, (ii) investigated the impact of 
statins versus placebo on circulating concentrations of Apo CIII, and, (iii) presentation of 
sufficient information on Apo CIII concentrations at baseline and at study end in both 
intervention and control groups or providing the net change values. Exclusion criteria were: (i) 
non-clinical studies, (ii) uncontrolled OR non-placebo-controlled studies, (iii) observational 
studies with case-control, cross-sectional or cohort design, and, (iv) lack of sufficient information 
on baseline or follow-up total circulating Apo CIII levels. 
Data extraction  
Eligible studies were reviewed and the following data were abstracted: 1) first author's name, 2) 
year of publication, 3) country where the study was performed, 4) study design, 5) number of 
participants in the statin and control groups, 6) type of statin used, 7) statin dose, 9) age, gender 
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and body mass index (BMI) of study participants, and, 10) baseline and follow-up concentrations 
of plasma lipids, lipoproteins and apolipoproteins (including Apo CIII). 
Quality assessment 
The quality of involved studies in this meta-analysis was evaluated using the Cochrane criteria.20 
Quantitative Data Synthesis 
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, 
NJ).21 A random-effects model (using DerSimonian-Laird method) and the generic inverse 
variance weighting method were used to compensate for the heterogeneity of studies in terms of 
study design, treatment duration, and the characteristics of populations being studied.22 Standard 
deviations (SDs) of the mean difference were calculated using the following formula: SD = 
square root [(SDpre-treatment)2 + (SDpost-treatment)2 – (2R × SDpre-treatment × SDpost-treatment)], assuming a 
correlation coefficient (R) = 0.5. Where standard error of the mean (SEM) was only reported, 
standard deviation (SD) was estimated using the following formula: SD = SEM × sqrt (n), where 
n is the number of subjects. All Apo CIII values were collated in mg/dL. Effect sizes were 
expressed as standardized mean difference (WMD) and 95% confidence interval (CI). In order to 
evaluate the influence of each study on the overall effect size, a sensitivity analysis was 
conducted using the leave-one-out method (i.e. removing one study each time and repeating the 
analysis).23,24 
Meta-regression 
As potential confounders of treatment response, changes in plasma lipid, lipoproteins and 
apolipoproteins levels were entered into a random-effects meta-regression model to explore their 
association with the estimated effect size on plasma Apo CIII levels.  
Publication bias 
Evaluation of funnel plot, Begg’s rank correlation and Egger’s weighted regression tests were 
employed to assess the presence of publication bias in the meta-analysis. When there was an 
evidence of funnel plot asymmetry, potentially missing studies were imputed using the "trim and 
fill" method.25 In case of significant result, the number of potentially missing studies required to 
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make the p-value non-significant was estimated using the “fail-safe N” method as another 
marker of publication bias. 
Results 
Overall, 58 articles were found following multi-database search. After screening of titles and 
abstracts, 16 articles were assessed in full text. Of these, 10 articles were excluded because of 
lack of reporting serum/plasma total Apo CIII concentrations (n=5), duplicate data report (n=4) 
and not being placebo-controlled (n=1), leaving 6 eligible articles with 10 treatment arms for 
meta-analysis.  
Study characteristics 
Data were pooled from 6 randomized placebo-controlled trials comprising a total of 802 subjects, 
including 444 and 358 participants in the statin and placebo arms (individuals in cross-over trials 
were considered in the treatment and control groups), respectively. The trials used different types 
and doses of statins.26-31 Selected studies were published between 199426,29 and 2008.30 The 
range of treatment duration was from 5 weeks27,28 to 30 weeks.28 Study designs of included trials 
were parallel26,28,29 and cross-over group.27,30,31 Selected studies enrolled subjects with 
hypercholesterolemia,26,29 coronary artery disease,26,29 obesity,27 type 2 diabetes28 and metabolic 
syndrome.30,31 The characteristics of the included clinical trials are shown in Table 1. 
 
Risk of bias assessment 
Almost all of the selected studies were characterized by lack of information about random 
sequence generation. All of the included trials had insufficient information regarding to 
allocation concealment. With respect to blinding of participants, personnel and outcome 
assessors, one study had a high risk of bias.26 However, all evaluated trials showed a low risk of 
bias for incomplete outcome data and selective outcome reporting.  
 
 
Quantitative data synthesis 
Meta-analysis of data from 10 statin treatment arms suggested a significant reduction of 
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circulating Apo CIII concentrations (WMD: -2.71, 95% CI: -3.74, -1.68, p<0.001; I2: 73.83%) 
(Figure 1). The effect size was robust in the leave-one-out sensitivity analysis (Figure 1) and not 
mainly driven by any single study. Subgroup analysis showed reduction of Apo CIII 
concentrations by atorvastatin (WMD: -4.74, 95% CI: -3.74, -1.68, p=0.002; I2: 84.02%), 
rosuvastatin (WMD: -2.68, 95% CI: -4.52, -0.84, p=0.004; I2: 0%) and lovastatin (WMD: -1.64, 
95% CI: -2.22, -1.07, p<0.001; I2: 0%) (Figure 2). 
Meta-regression 
Random-effects meta-regression was performed to assess the impact of potential confounders on 
the effects of statins on plasma Apo CIII levels. The results suggested a significant positive 
association between the changes in plasma concentrations of Apo CIII and those of LDL-C 
(slope: 0.06; 95% CI: 0.001, 0.13; p=0.047), apoB (slope: 0.12; 95% CI: 0.01, 0.22; p=0.026) 
and TGs (slope: 0.03; 95% CI: 0.01, 0.05; p=0.015), and a borderline non-significant association 
with changes in plasma Apo AI levels (slope: 0.27; 95% CI: -0.001, 0.55; p=0.051). No 
significant association was found between changes in plasma Apo CIII and HDL-C 
concentrations (slope: -0.47; 95% CI: -1.85, 0.90; p=0.500) (Figure 3). 
Publication bias 
Visual inspection of Begg's funnel plots revealed a slight asymmetry in the meta-analyses of 
statin's effects on plasma Apo CIII levels. Begg's rank correlation (p=0.074) but not Egger's 
regression test (p=0.116) also suggested the presence of potential but slight publication bias. 
Using “trim and fill” method, one potentially missing study was imputed yielding an adjusted 
effect size of -2.92 (-3.94, -1.89) (Figure 4). The results of “fail-safe N” test suggested that 252 
missing studies would be required to make the observed significant result non-significant. 
 
Discussion 
The results of this meta-analysis suggest that treatment with statins significantly reduces plasma 
Apo CIII levels.   
Although elevated LDL-C is the primary target for treatment and the drugs of choice are statins, 
many patients have atherogenic dyslipidemia. This lipoprotein disturbance is characterized by 
increased levels of TGs usually accompanied by decreased levels of HDL-C and normal or only 
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moderately raised concentrations of LDL-C.32,33 LDL particles in this lipoprotein disturbance are 
smaller and more dense and are considered to be more atherogenic than larger buoyant LDL 
particles.34,35 
Atherogenic dyslipidemia often occurs in patients with metabolic syndrome and/or type 2 
diabetes mellitus (T2DM). Apo CIII is contained in TG-rich particles such as very low density 
lipoprotein (VLDL) and TG-rich remnant particles but also in some LDL particles which are 
enriched with TGs.36-39 Therefore, in patients with elevated TGs, especially in those with 
metabolic syndrome and/or T2DM, the levels of Apo CIII are also elevated.40,41 This may be 
attributed to increased production of Apo CIII in subjects with obesity and hypertriglyceridemia 
which might be related to the effect of insulin resistance in increasing the expression of Apo CIII 
mediated by forkhead box O1.40,42 The role of Apo CIII has also been implicated in beta-cell 
dysfunction and influence on pancreatic microvasculature thus participating in etiopathogenesis 
of T2DM43-45 but also in atherogenesis by directly activating pro-inflammatory and atherogenic 
mechanisms in endothelial cells of the arterial wall and monocytes.46-48 
Fibrates are the treatment of choice for hypertriglyceridemia and they have been demonstrated to 
reduce apoC-III as a possible mechanism of TG reduction.49 Statins also decrease elevated TG 
levels. The mechanism involved in the TG lowering effect of statins has not been fully 
elucidated. It may involve decreasing the production rate of VLDLs; these effects seem to be 
dependent on pre-treatment circulating VLDL concentrations.  
It has also been demonstrated that statins decrease hepatic apoB mRNA and apoB secretion, 
leading to reduced plasma VLDL apoB levels. In addition, statin therapy can enhance plasma 
clearance of TG-rich lipoproteins. This increased clearance may explain the effect of statins on 
plasma Apo CIII levels as shown in this meta-analysis. Particularly a combination treatment with 
a statin and a fibrate, usually fenofibrate, was advocated, especially for atherogenic 
dyslipidemia.50,51 In this context, ezetimibe, another LDL-C lowering drug (acting at the level of 
intestinal cholesterol transport), can, on the other hand, increase the TG-lowering effect of statins 
and this effect may be more obvious at higher baseline TG levels.52-55 
 
More recently a new drug - volanesorsen - a second generation antisense oligonucleotide that 
reduces the levels of Apo CIII mRNA is being evaluated.56,57 Nevertheless, statins are and will be 
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used for treatment of atherogenic dyslipidemia for quite some time because of their price which 
will be considerably less than for volanesorsen. It has been shown in experimental conditions 
that statins decrease Apo Apo CIII synthesis in human HepG2 cells due to activating the 
peroxisome proliferator-activated receptor-α pathway via inhibition of ρ-signaling, thereby 
repressing Apo CIII mRNA expression.58,59 However, such an effect of statins on Apo CIII in 
humans has not been confirmed so far. 
Our study has some limitations including the heterogeneity with respect to the use of different 
statins, doses, duration of treatment, patient characteristics and also baseline TG levels. The 
number of studies was too low to allow subgroup analysis of the effects of individual statins. 
Conclusions 
This meta-analysis suggests that treatment with statins significantly reduces plasma Apo CIII 
levels. This can, at least to some extent, explain why apart from an LDL-C lowering effect, 
statins also have a TG-lowering effect. More research should address the effect of different 
statins on Apo CIII levels/activity in order to identify possible differences between these drugs.  
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FIGURE LEGENDS  
Figure 1. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of statin therapy on circulating Apo C-III concentrations. Lower plot shows the results of 
leave-one-out sensitivity analysis. Symbols "a" and "b" denote different statin treatment arms 
reported in a single study. 
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of different statins on circulating Apo C-III concentrations. Symbols "a" and "b" denote 
different statin treatment arms reported in a single study. 
Figure 3. Meta-regression bubble plots of the association between mean changes in plasma Apo 
C-III concentrations and changes in plasma concentrations of LDL-C, HDL-C, triglycerides, 
apoB and apo A-I following treatment with statins. The size of each circle is inversely 
proportional to the variance of change. 
 
Figure 4. Funnel plot detailing publication bias in the studies reporting the impact of statins on 
plasma Apo C-III concentrations. Open and closed circles represent reported studies and 
potentially missing studies imputed using "trim and fill" method. 
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Author Study design Target 
Population 
Treatment 
duration 
n Study groups Age, 
years 
Female 
(n, %) 
BMI, 
(kg/m2) 
Total 
cholesterol 
(mg/dl) 
LDL 
cholesterol 
(mg/dl)* 
HDL 
cholesterol 
(mg/dl) 
Triglyceride
s 
(mg/dl) 
ApoC-III 
(mg/dl) 
% Change 
vs 
baseline** 
% 
Change 
vs 
placebo 
ApoC-III 
Assay method 
Alaupovic 
et al. 
(1994) 
Randomized, 
placebo-
controlled 
Hypercholeste-
rolemia and 
CAD 
2 years  
 
32 
102 
 
31 
105 
 
Lovastatin 80 mg/day 
   Lp 
   No Lp 
Placebo 
   Lp 
   No Lp 
 
 
58.7±6.7 
ND 
 
58.5±6.1 
ND 
 
 
3 (10) 
ND 
 
3 (10) 
ND 
 
 
ND 
ND 
 
ND 
ND 
 
 
226.3±24.3 
232.3±23.2 
 
233.5±21.1 
230.5±24.5 
 
 
151.6±24.3 
158.1±24.2 
 
156.1±26.1 
156.7±20.4 
 
 
42.0±7.3 
42.7±11.1 
 
43.1±8.3 
42.7±9.2 
 
 
163.9±81.4 
159.0±9.0 
 
172.7±91.3 
155.5±67.6 
 
 
12.3±3.9 
12.7±4.0 
 
13.0±3.8 
13.2±7.1 
 
 
-10.5% 
-14.4% 
 
3.0% 
0.0% 
 
 
Lp  
-18% 
 
 
No Lp  
-17% 
 
 
Electroimmuno-
assay 
Chan et al. 
(2010) 
Randomized, 
double-blind, 
placebo-
controlled, 
cross-over 
Obese men 6 weeks  
11 
9 
11 
8 
 
Placebo 
Atorvastatin 40 
mg/day  
Fish oil 
Atorvastatin 40 
mg/day + fish oil 
 
50±12 
54±9 
58±8 
56±8 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
32.0±2.8 
33.7±4.5 
35.3±4.6 
32.3±2.7 
 
228.2±3.9 
224.3±7.7 
232.0±7.7 
228.2±7.7 
 
146.9±3.9 
150.8±7.7 
154.7±7.7 
146.9±11.6 
 
ND 
ND 
ND 
ND 
 
150.6±17.7 
150.6±8.9 
177.1±35.4 
177.1±17.7 
 
15.9±1.0 
15.7±7.0 
15.9±1.2 
16.4±1.3 
 
-10.0% 
-15.2% 
-10.6% 
-27.4% 
 
 
-6.9% 
-0.6% 
-16.7% 
 
 
Immunoturbido-
metry 
Dallinga-
Thie et al. 
(2006) 
Randomized, 
double-blind, 
placebo-
controlled 
Type 2 diabetes 30 weeks  
71 
72 
72 
 
Placebo 
Atorvastatin 10 
mg/day 
Atorvastatin 80 
mg/day 
 
59±8 
60±8 
60±8 
 
ND 
ND 
ND 
 
32.2±6.1 
30.0±3.8 
30.4±4.5 
 
232.0±34.8 
228.2±34.8 
232.0±34.8 
 
ND 
ND 
ND 
 
40.6±8.1 
40.6±10.1 
39.8±9.3 
 
248.0±88.6 
239.1±79.7 
265.7±97.4 
 
41.2±9.0 
39.8±9.4 
43.2±11.
2 
 
-0.5% 
-21.1% 
-27.2% 
 
 
-22.4% 
-24.1% 
 
Electroimmuno-
assay 
Hodis et al. 
(1994) 
Randomized, 
double-blind, 
placebo-
controlled 
Hypercholeste-
rolemia and 
CAD 
2 years 220 
114 
106 
Overall 
Lovastatin 80 mg/day 
Placebo 
ND 
ND 
ND 
 
ND 
ND 
ND 
ND 
ND 
ND 
230.1±14.8 
ND 
ND 
156.0±23.7 
ND 
ND 
42.3±10.3 
ND 
ND 
160.4±75.6 
ND 
ND 
12.7±5.9 
ND 
ND 
 
-11.0% 
0.7% 
 
-10.9% 
 
Electroimmuno-
assay 
Ooi et al. 
(2008) 
Randomized, 
double-blind, 
placebo-
controlled, 
cross-over 
Men with 
metabolic 
syndrome 
5 weeks 12 
12 
12 
12 
Overall 
Placebo 
Rosuvastatin 10 
mg/day 
Rosuvastatin 40 
mg/day 
48.6±8.5 
ND 
ND 
ND 
0 (0.0) 
ND 
ND 
ND 
33.6±4.9 
ND 
ND 
ND 
220±29 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
38±4 
ND 
ND 
ND 
202±66 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
 
NC 
NC 
NC 
 
 
-12.2% 
-23.0% 
 
Electroimmuno-
diffusion 
Watts et al. 
(2003) 
Randomized, 
double-blind, 
placebo-
controlled, 
cross-over 
Men with 
metabolic 
syndrome 
5 weeks 11 
11 
11 
Overall 
Atorvastatin 40 
mg/day 
Placebo 
46.3±6.9 
ND 
ND 
0 (0.0) 
ND 
ND 
30.5±2.6 
ND 
ND 
227.4±19.3 
ND 
ND 
152.4±26.7 
ND 
ND 
36.3±5.4 
ND 
ND 
215.2±92.1 
ND 
ND 
ND 
ND 
ND 
 
NC 
NC 
 
-18.0% 
 
Immunoturbido-
metry 
Values are expressed as mean ± SD 
** Values are expressed as mean ± SEM 
* LDL values were calculated by the Friedwald equation 
Abbreviations: ND, no data; BMI, body mass index; CAD, coronary artery disease; NC, not calculable. 
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Highlights:  
• Results suggest that treatment with statins reduces plasma Apo CIII levels  
• This can explain why statins also have a TG-lowering effect 
• This effect of statins might contribute to their antiatherosclerotic effects 
 
